The primary purpose of this study is to evaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies including refractory acute leukemia. The transplant procedure was determined in detail according to the previously published report showing a high survival, so that the investigators could expect a similar result.
Although cord blood is considered as an alternative donor source for allogeneic hematopoietic stem cell transplantation, its procedure has yet to be standardized. Recently, a single institute result of cord blood transplantation for adult patients with hematologic malignancies have been reported by Takahashi et al (Blood 2004:104;3813-3820), in which the survival was significantly better than that of bone marrow transplantation from unrelated donor. The purpose of this study was to reevaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies using the same transplant procedures in a multi-institutional setting.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
33
unrelated cord blood transplantation
Total body irradiation (TBI) 12Gy
cyclophosphamide 120mg/kg
cytarabine 3g/m2x4
Keio University School of Medicine
Tokyo, Japan
Non-relapse mortality at 1 year
Time frame: 1 year
Engraftment
Time frame: day 56
Disease free survival
Time frame: 1 year
Overall survival
Time frame: 1 year
Incidence of acute and chronic graft-versus-host disease
Time frame: day100 and 1 year
Incidence of infectious complication
Time frame: 1year
Duration of hospitalization
Time frame: 1 year
Immune reconstitution after transplantation
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.